Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

Sponsor
College of Physicians and Surgeons Pakistan
Study ID
NCT07326631
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Finerenone — DRUG
    To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.

Study Details

To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.

Key Dates

Start date
Jan 1, 2026
Status verified
Dec 2025
Primary completion
Jun 30, 2026
Completion
Jul 1, 2026

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Finerenone Group
    Finerenone Drug

Primary Outcome Measure

Number of Participants with Renal Function Decline post finerinone therapy [ Time Frame: From enrollment to the end of treatment at 06 months ]

Central Contacts

Related Studies